A study to evaluate the real world effectiveness of Inhaled corticosteroid/Long acting beta agonist combination and assessment of Health related quality of life among COPD patients on this therapy

Department of Pharmacology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Male and female patients of age 40 years or more.
•2. Patient with at least 1 Inpatient Department visit with primary diagnosis for COPD (Spirometry: post bronchodilator- FEV1/FVC < 0.70).
•3. Patient with at least 1 Emergency Department visit with COPD diagnosis.
•4. Patient not having an exacerbation for one month prior to study entry.
•5. Patient on inhalational therapy for 2-3 weeks.

•1. Patient diagnosed with asthma or other non-COPD respiratory disorder.
•2. Patient with history of any previous lung volume reduction surgery and/or lung transplantation.
•3. Patient who requires oxygen therapy for at least 12 hours per day.
•4. Any exclusionary co-morbid medical condition (cystic fibrosis, bronchiectasis, respiratory cancer, pulmonary fibrosis, pneumoconiosis, sarcoidosis), or any other condition likely to cause death within 3 years.
•5. Current use of oral/injectable corticosteroid therapy.
•6. Patients (diagnosed with cancer) who received >= 180 days of oral corticosteroids (OCS) in the 12 month pre-index period.
•7. Immuno-compromised (HIV +ve) patients
•8. Patients who are not willing to give written informed consent.

发起方